Low-Dose Radiation Therapy for Mycosis Fungoides

Overseen by Bouthaina S Dabaja

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: M.D. Anderson Cancer Center

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This phase II trial studies how well ultra low dose radiation therapy works in treating patients with mycosis fungoides. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving ultra low doses of radiation may help control the disease and reduce side effects compared to treatment with higher doses.

Research Team

Bouthaina S Dabaja

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for patients with mycosis fungoides, a type of skin lesion. Eligible participants can have any stage of the disease and may be undergoing other treatments. They must not apply certain topical agents to the lesion before joining, and women who can become pregnant need a negative pregnancy test.

Inclusion Criteria

I have mycosis fungoides with skin symptoms.

I have at least one visible tumor that can be measured.

My cancer lesions are less than or equal to 1 cm tall and I want them treated.

Exclusion Criteria

Pregnant patients do not meet inclusion criteria for radiation therapy

I have active lupus or scleroderma.

My skin lesions are not taller than 1 cm from the surface.

Treatment Details

Interventions

• Ultra Low Dose Radiation Therapy (Radiation Therapy)

Trial Overview The study tests ultra low dose radiation therapy's effectiveness in treating mycosis fungoides. It aims to control the disease with fewer side effects than higher doses. Patients' quality of life will also be assessed through questionnaires.

Participant Groups

Group I: Treatment (ultra low dose radiation therapy) Experimental Treatment 3 Interventions

Patients undergo ultra low dose radiation therapy at the discretion of the treating physician.

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials

3,107

Recruited

1,813,000+

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School